论文部分内容阅读
新药Sulmazol(AR-L_(115)BS)能增强心肌的收缩性,并有扩张血管的特点。对该药发挥正性肌力作用的细胞机制尚缺乏了解,但不同于儿茶酚胺、洋地黄、黄嘌呤或高血糖素的作用。Sulmazol不直接兴奋心肌的腺苷环化酶,但抑制心肌磷酸二酯酶,可使细胞内环磷酸腺甙增多。收缩装置的敏感性可能直接参与Sulma-zol的作用机制,由健康志愿者接受异博定后能
New drug Sulmazol (AR-L_ (115) BS) can enhance myocardial contractility and dilate blood vessels. The lack of understanding of the cellular mechanisms by which the drug exerts its inotropic effect is distinct from the effects of catecholamines, digitalis, xanthine, or glucagon. Sulmazol does not directly excite adenylyl cyclase in the myocardium, but inhibits cardiac phosphodiesterase and increases intracellular cyclic adenosine monophosphate. The sensitivity of contractile devices may be directly involved in the mechanism of action of Sulma-zol, after receiving different dosages by healthy volunteers